APPLICATION
NDA018776
TYPE
NDA
ORIGINAL APPROVAL
1984-04-30
LATEST ACTION
2010-11-22
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued
Products
NORCURON · ReferenceDiscontinued
VECURONIUM BROMIDE 20MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
NORCURON · ReferenceDiscontinued
VECURONIUM BROMIDE 10MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE · INJECTION
Approval history
2001-02-02Manufacturing (CMC) · Supplement 26 · standardAP
2000-08-24Labeling · Supplement 23 · standardAP
2000-04-11Manufacturing (CMC) · Supplement 25 · standardAP
1999-03-15Manufacturing (CMC) · Supplement 24 · standardAP
1997-06-19Manufacturing (CMC) · Supplement 22 · standardAP
1994-05-10Manufacturing (CMC) · Supplement 20 · standardAP
1994-02-28Manufacturing (CMC) · Supplement 21 · standardAP
1992-01-03Labeling · Supplement 16 · standardAP
1992-01-03Manufacturing (CMC) · Supplement 15 · standardAP
1990-10-05Manufacturing (CMC) · Supplement 19 · standardAP
1989-07-14Manufacturing (CMC) · Supplement 17 · standardAP
1988-02-08Manufacturing (CMC) · Supplement 10 · standardAP
1988-02-08Labeling · Supplement 11 · standardAP
1987-12-29Efficacy · Supplement 7 · standardAP
1987-01-28Manufacturing (CMC) · Supplement 8 · standardAP
1987-01-28Labeling · Supplement 4 · standardAP
1987-01-28Labeling · Supplement 9 · standardAP
1987-01-28Manufacturing (CMC) · Supplement 3 · standardAP
1986-05-12Labeling · Supplement 6 · standardAP
1986-05-12Manufacturing (CMC) · Supplement 5 · standardAP
1984-12-17Labeling · Supplement 2 · standardAP
1984-12-17Manufacturing (CMC) · Supplement 1 · standardAP
1984-04-30Type 1 - New Molecular Entity · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.